RenovoRx (RenovoRx) Scaled Net Operating Assets : -1.79 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is RenovoRx Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

RenovoRx's operating assets for the quarter that ended in Mar. 2024 was $0.40 Mil. RenovoRx's operating liabilities for the quarter that ended in Mar. 2024 was $3.02 Mil. RenovoRx's Total Assets for the quarter that ended in Dec. 2023 was $1.47 Mil. Therefore, RenovoRx's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was -1.79.

RenovoRx Scaled Net Operating Assets Historical Data

The historical data trend for RenovoRx's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovoRx Scaled Net Operating Assets Chart

RenovoRx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

-5.74

-6.02

0.08

-0.02

-0.57

RenovoRx Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial													-0.06	-1.05	-0.51	-1.19	-1.79

Competitive Comparison of RenovoRx's Scaled Net Operating Assets

For the Biotechnology subindustry, RenovoRx's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RenovoRx's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovoRx's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where RenovoRx's Scaled Net Operating Assets falls into.

RenovoRx Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

RenovoRx's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(0.293	-	4.466)	/	7.265
=	-0.57

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	1.466	-	1.173
=	0.293

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	4.466	-	0	-	0
=	4.466

RenovoRx's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(0.399	-	3.021)	/	1.466
=	-1.79

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	4.788	-	4.389
=	0.399

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	3.021	-	0	-	0
=	3.021

RenovoRx Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of RenovoRx's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

RenovoRx (RenovoRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovoRx Inc (NAS:RNXT) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

4546 El Camino Real, Suite B1, Los Altos, CA, USA, 94022

Website

https://www.renovorx.com

RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 pancreatic cancer clinical trial for its lead product candidate RenovoGem.

Executives

Angela Nelms	officer: Chief Operating Officer	C/O RENOVORX, INC., 4546 EL CAMINO REAL, SUITE B1, LOS ALTOS CA 94022
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
James M Ahlers	officer: Chief Financial Officer	2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Ramtin Agah	director, officer: Chief Medical Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Shaun Bagai	director, officer: Chief Executive Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Bank Of The West	10 percent owner	PO BOX 60078, LOS ANGELES CA 90060
Una S Ryan	director	329 HAMMOND STREET, CHESTNUT HILL MA 02467
David Diamond	director	29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Laurence Marton	director	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kirsten Angela Macfarlane	director	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Christopher John Lehman	officer: Chief Financial Officer	65 OAK RIDGE ROAD, BERKELEY, BERKELEY CA 94705
Paul Manners	officer: Chief Financial Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kamran Najmabadi	10 percent owner	3114 DAVID AVE., PALO ALTO CA 94303
Najmabadi Family Trust Dated April 22, 2021	10 percent owner	3114 DAVID AVE., PALO ALTO CA 94303